Compare AbCellera Biologics Inc (ABCL) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Huntington Bancshares Incorporated — how do they compare? AbCellera Biologics Inc trades at $7.17 (market cap $2.35B), while Huntington Bancshares Incorporated trades at $17.46 (market cap $36.50B). The key difference: Huntington Bancshares Incorporated is far larger — about 15.5× AbCellera Biologics Inc's market cap, and Huntington Bancshares Incorporated pays a 3.44% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | HBAN | |
|---|---|---|
Market Cap | $2.35B | $36.50B |
Sector | Health | Financials |
52-Week High | $8.12 | $19.27 |
52-Week Low | $2.78 | $15.02 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Huntington Bancshares (HBAN) trades at $18.01, up 0.84% with bullish technical indicators and strong analyst support. The stock shows solid fundamentals with Q1 2026 EPS beating expectations at $0.26 vs. $0.23, revenue growth to $8.13B in 2025, and a reasonable P/E of 13.77. Recent news highlights successful Texas expansion and banking tech awards, while cash flow trends show consistent operational strength.
HBAN presents a compelling buy case with 51% analyst buy ratings and a $19.90 price target offering 10% upside. Key opportunities include M&A synergies and digital banking growth, though risks remain from integration challenges and competitive pressures in regional banking markets. The stock's current valuation and growth trajectory support a positive outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
